Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DalCor Pharmaceuticals

www.Dalcorpharma.com

Latest From DalCor Pharmaceuticals

DalCor Keeps Faith In CETP Biomarker, Despite No Dice For Merck's REVEAL Genetic Analysis

Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.

Clinical Trials Research & Development

Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health

This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.

Appointments BioPharmaceutical

Amgen Focuses On Pipeline As Mature Products Face Declining Demand

Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.

Sales & Earnings Business Strategies

Merck Calls It Quits On Anacetrapib

Despite success in REVEAL outcomes trial, Merck will not submit the for the cholesteryl ester transfer protein (CETP) inhibitor for regulatory approval.

Drug Review Research & Development
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • DalCor Pharmaceuticals
  • Senior Management
  • Robert McNeil, CEO
    Michael Dixon, CFO
    Donald M Black, MD, CMO
    Louise Proulx, PhD, Chief Dev. Officer
  • Contact Info
  • DalCor Pharmaceuticals
    Phone: (514) 564-6474
    Sherbrooke St. West, Ste. 408
    Montreal, H3A 2R7
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register